Prostate Cancer and Prostatic Diseases

Article	Citations
Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2–10 ng/mL	95
How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer	94
Cancer detection rates of the PI-RADSv2.1 assessment categories: systematic review and meta-analysis on lesion level and patient level	57
Advances in PSMA-targeted therapy for prostate cancer	50
Depression, anxiety, and suicidality in patients with prostate cancer: a systematic review and meta-analysis of observational studies	49
A systematic review and meta-analysis of the diagnostic accuracy of biparametric prostate MRI for prostate cancer in men at risk	48
The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches	43
Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men	39
Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies	37
Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer—a systematic review and meta-analysis	36
Management of prostate cancer patients during COVID-19 pandemic	35
Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology	35
Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors	35
3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction	34
Racial disparities in prostate cancer among black men: epidemiology and outcomes	34
Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide	33
PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review	33
Crosstalk between COVID-19 and prostate cancer	31
The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer	28
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and networ	27
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate	27
Clinical considerations for the management of androgen indifferent prostate cancer	27
Exercise modulation of tumour perfusion and hypoxia to improve radiotherapy response in prostate cancer	26
Treating the patient and not just the cancer: therapeutic burden in prostate cancer	26
Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study	25

Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms?: a systematic review	24
Associations of fat and muscle mass with overall survival in men with prostate cancer: a systematic review with meta-analysis	24
Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study	24
Transrectal versus transperineal prostate biopsy under intravenous anaesthesia: a clinical, microbiological and cost analysis of 2048 cases over 11 years at a tertiary institution	24
The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients	24
Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth	23
Shared decision making and prostate-specific antigen based prostate cancer screening following the 2018 update of USPSTF screening guideline	22
BRD4 regulates key transcription factors that drive epithelial–mesenchymal transition in castration-resistant prostate cancer	22
Effects of high-intensity interval training compared with resistance training in prostate cancer patients undergoing radiotherapy: a randomized controlled trial	21
Disparities in germline testing among racial minorities with prostate cancer	21
The microbiome and prostate cancer	21
Contemporary trends in the surgical management of urinary incontinence after radical prostatectomy in the United States	20
Animal models of benign prostatic hyperplasia	20
Diagnostic accuracy of magnetic resonance imaging targeted biopsy techniques compared to transrectal ultrasound guided biopsy of the prostate: a systematic review and meta-analysis	20
TP53 alterations of hormone-naïve prostate cancer in the Chinese population	20
Robotic assisted simple prostatectomy versus other treatment modalities for large benign prostatic hyperplasia: a systematic review and meta-analysis of over 6500 cases	20
The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis	20
Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses	19
The effect of exercise training on cardiometabolic health in men with prostate cancer receiving androgen deprivation therapy: a systematic review and meta-analysis	19
Psychological distress in men with prostate cancer undertaking androgen deprivation therapy: modifying effects of exercise from a year-long randomized controlled trial	19
Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer	19
Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies	18
Diagnostic ability of Ga-68 PSMA PET to detect dominant and non-dominant tumors, upgrading and adverse pathology in patients with PIRADS 4–5 index lesions undergoing radical prostatectomy	18
Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer	17
Rezūm water vapor therapy in multimorbid patients with urinary retention and catheter dependency	17
Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics	17
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer	17
The effectiveness of psychological intervention for depression, anxiety, and distress in prostate cancer: a systematic review of literature	17
Barriers and facilitators related to undertaking physical activities among men with prostate cancer: a scoping review	17
Enhancement of prostate cancer diagnosis by machine learning techniques: an algorithm development and validation study	17
Systematic review of the impact of a plant-based diet on prostate cancer incidence and outcomes	16
Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer	16
Comparison of Retzius-sparing and conventional robot-assisted laparoscopic radical prostatectomy regarding continence and sexual function: an updated meta-analysis	16
Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer	16
Reducing the number of systematic biopsy cores in the era of MRI targeted biopsy—implications on clinically-significant prostate cancer detection and relevance to focal therapy planning	16
Risk of prostate cancer in men with HIV/AIDS: a systematic review and meta-analysis	16
Clinical significance of STEAP1 extracellular vesicles in prostate cancer	16
Evaluation of a low-intensity shockwave therapy for chronic prostatitis type IIIb/chronic pelvic pain syndrome: a double-blind randomized sham-controlled clinical trial	16
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer	15
Global burden and temporal trends of lower urinary tract symptoms: a systematic review and meta-analysis	15
Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative	15
Effects of yoga in men with prostate cancer on quality of life and immune response: a pilot randomized controlled trial	15
Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study	15
Statins and prostate cancer—hype or hope? The epidemiological perspective	15
Oncological outcomes of cribriform histology pattern in prostate cancer patients: a systematic review and meta-analysis	15
What is the minimal dose for resistance exercise effectiveness in prostate cancer patients? Systematic review and meta-analysis on patient-reported outcomes	15
The obesity paradox in metastatic castration-resistant prostate cancer	14
Prostate epithelial genes define therapy-relevant prostate cancer molecular subtype	14
A comparative study of PCS and PAM50 prostate cancer classification schemes	14
Prostate cancer detection: a systematic review of urinary biosensors	14

Quality of information and appropriateness of ChatGPT outputs for urology patients	14
Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer	14
PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer	14
Physical activity decreases the risk of cancer reclassification in patients on active surveillance: a multicenter retrospective study	14
Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis	14
Clinical implications of genomic alterations in metastatic prostate cancer	13
Poor clinical guideline adherence and inappropriate testing for incident lower urinary tract symptoms associated with benign prostatic hyperplasia	13
A cross-sectional study on gut microbiota in prostate cancer patients with prostatectomy or androgen deprivation therapy	13
Artificial intelligence for target prostate biopsy outcomes prediction the potential application of fuzzy logic	13
A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer	13
PSA density is complementary to prostate MP-MRI PI-RADS scoring system for risk stratification of clinically significant prostate cancer	13
A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)	13
Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England	13
18F-Fluciclovine PET/CT performance in biochemical recurrence of prostate cancer: a systematic review	13
Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer	13
Long-term outcomes of prostate radiotherapy for newly-diagnosed metastatic prostate cancer	12
Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score	12
Early oncological control following partial gland cryo-ablation: a prospective experience specifying reflex MRI guided biopsy of the ablation zone	12
Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids	12
Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer	12
The use of a novel smartphone app for monitoring male luts treatment during the COVID-19 outbreak	12
Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies	12
Oncological and functional outcome after partial prostate HIFU ablation with Focal-One®: a prospective single-center study	12
Elective procedures for prostate cancer in the time of Covid-19: a multidisciplinary team experience	12
Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies	12
Composite urinary and sexual outcomes after Rezum: an analysis of predictive factors from an Italian multi-centric study	12
CASC11 promotes aggressiveness of prostate cancer cells through miR-145/IGF1R axis	12
Effects of dietary omega-3 fatty acids on orthotopic prostate cancer progression, tumor associated macrophages, angiogenesis and T-cell activation—dependence on GPR120	12
The association of cancer-specific anxiety with disease aggressiveness in men on active surveillance of prostate cancer	12
Changes in body composition and lipid profile in prostate cancer patients without bone metastases given Degarelix treatment: the BLADE prospective cohort study	11
Common genetic and clinical risk factors: association with fatal prostate cancer in the Cohort of Swedish Men	11
Patient- and tumor-level risk factors for MRI-invisible prostate cancer	11
Cardiac biomarkers in patients with prostate cancer and cardiovascular disease receiving gonadotrophin releasing hormone agonist vs antagonist	11
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk	11
One-year outcomes after treatment with a drug-coated balloon catheter system for lower urinary tract symptoms related to benign prostatic hyperplasia	11
Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection	11
Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer	11
Comprehensive analysis of complications after transperineal prostate biopsy without antibiotic prophylaxis: results of a multicenter trial with 30 days’ follow-up	11
Supervised exercise therapy compared with no exercise therapy to reverse debilitating effects of androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis	10
Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center	10
High expression of Sterol-O-Acyl transferase 1 (SOAT1), an enzyme involved in cholesterol metabolism, is associated with earlier biochemical recurrence in high risk prostate cancer	10
What is the effect of MRI with targeted biopsies on the rate of patients discontinuing active surveillance? A reflection of the use of MRI in the PRIAS study	10
Urine spermine and multivariable Spermine Risk Score predict high-grade prostate cancer	10
The intraprostatic immune environment after stereotactic body radiotherapy is dominated by myeloid cells	10
Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2–ERG fusions	10
Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine	10
The UroLift implant: mechanism behind rapid and durable relief from prostatic obstruction	10
Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control	10
Race reporting and diversity in US food and drug administration (FDA) registration trials for prostate cancer; 2006–2020	10
Outcomes and clinical predictors of extracorporeal shock wave therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome: a prospective randomized double-blind placebo-controlled cli	10
Predictive role of node-rads score in patients with prostate cancer candidates for radical prostatectomy with extended lymph node dissection: comparative analysis with validated nomograms	10
Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience	9
Comprehensive Lifestyle Improvement Program for Prostate Cancer (CLIPP) is associated with improvement in weight and components of metabolic syndrome in men exposed to androgen deprivation therapy for	9
Mapping PSA density to outcome of MRI-based active surveillance for prostate cancer through joint longitudinal-survival models	9
The EXPANDER-1 trial: introduction of the novel Urocross™ Expander System for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH)	9
Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223	9
Dietary inflammatory index and prostate cancer risk: MCC-Spain study	9
Rationale and protocol for randomized study of transrectal and transperineal prostate biopsy efficacy and complications (ProBE-PC study)	9
Quality of information and appropriateness of ChatGPT outputs for urology patients	9
The effect of preoperative membranous urethral length on likelihood of postoperative urinary incontinence after robot-assisted radical prostatectomy	9
MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naïve patients: follow-up of a PRECISION trial-like retrospective cohort	9
Sectoral cancer detection and tolerability of freehand transperineal prostate biopsy under local anaesthesia	9
Nomograms in PCa: where do we stand	9
The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population	8
Risk of erectile dysfunction after modern radiotherapy for intact prostate cancer	8
Survival trends for patients with primary metastatic prostate cancer before and after the introduction of new antitumor drugs	8
The transition from transrectal to transperineal prostate biopsy without antibiotic prophylaxis: Cancer detection rates and complication rates	8
Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials	8
Use of multiparametric magnetic resonance imaging (mpMRI) in active surveillance for low-risk prostate cancer: a scoping review on the benefits and harm of mpMRI in different biopsy scenarios	8
The impact of a fasting mimicking diet on the metabolic health of a prospective cohort of patients with prostate cancer: a pilot implementation study	8
Racial disparities in treatment delay among younger men with prostate cancer	8
Real-world use of MRI for risk stratification prior to prostate biopsy	8
Quantifying observational evidence for risk of dementia following androgen deprivation therapy for prostate cancer: an updated systematic review and meta-analysis	8
Development of a novel nomogram to identify the candidate to extended pelvic lymph node dissection in patients who underwent mpMRI and target biopsy only	8
Modifiable risk factors for prostate cancer in low- and lower-middle-income countries: a systematic review and meta-analysis	8
EXIT from TRansrectal prostate biopsies (TREXIT): sepsis rates of transrectal biopsy with rectal swab culture guided antimicrobials versus freehand transperineal biopsy	8
Obesity and biochemical recurrence in clinically localised prostate cancer: a systematic review and meta-analysis of 86,490 patients	8
Can fewer transperineal systematic biopsy cores have the same prostate cancer detection rate as of magnetic resonance imaging/ultrasound fusion biopsy?	8
Single-port transvesical versus open simple prostatectomy: a perioperative comparative study	8
Characterisation of cell lines derived from prostate cancer patients with localised disease	8

Trends and practices for managing low-risk prostate cancer: a SEER-Medicare study	8
Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24	8
Instagram and prostate cancer: using validated instruments to assess the quality of information on social media	8
LUTS/BPH and SARS-COV2: when a misunderstanding in the correct physiopathology results in incorrect associations	8
Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs?	8
MRI-targeted biopsy cores from prostate index lesions: assessment and prediction of the number needed	8
Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases	8
KLK3 and TMPRSS2 for molecular lymph-node staging in prostate cancer patients undergoing radical prostatectomy	8
Discovery of a new candidate drug to overcome cabazitaxel-resistant gene signature in castration-resistant prostate cancer by in silico screening	8
Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients	8
The cost-effectiveness of prostate health index for prostate cancer detection in Chinese men	8
Association between environmental quality and prostate cancer stage at diagnosis	8
Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer	8